Relief Therapeutics Holding SA RLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RLF is a good fit for your portfolio.
News
-
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
-
Relief Therapeutics has Published its Annual Report
-
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
-
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
-
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
-
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
-
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Trading Information
- Previous Close Price
- CHF 1.22
- Day Range
- CHF 1.23–1.29
- 52-Week Range
- CHF 1.15–7.10
- Bid/Ask
- CHF 1.25 / CHF 1.30
- Market Cap
- CHF 15.68 Mil
- Volume/Avg
- 4,668 / 17,675
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.38
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
Valuation
|
Metric
|
RLF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.33 |
Price/Sales | 2.38 |
Price/Cash Flow | — |
Price/Earnings
RLF
Financial Strength
|
Metric
|
RLF
|
|---|---|
Quick Ratio | 2.52 |
Current Ratio | 2.65 |
Interest Coverage | −337.72 |
Quick Ratio
RLF
Profitability
|
Metric
|
RLF
|
|---|---|
Return on Assets (Normalized) | −13.29% |
Return on Equity (Normalized) | −18.43% |
Return on Invested Capital (Normalized) | −17.04% |
Return on Assets
RLF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xvrtqgdr | Skkp | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gfdvcqqxy | Kkvtcsm | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fgzrqswn | Srhqbt | $105.3 Bil | |
MRNA
| Moderna Inc | Qcsylzkq | Dhwtk | $47.0 Bil | |
ARGX
| argenx SE ADR | Tyjtwdlb | Scpw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qgcppgk | Xzxn | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lfxjrnwt | Zkjry | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cpzszpdb | Vgkylm | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ngfjdvnyww | Jcmkfz | $12.7 Bil | |
INCY
| Incyte Corp | Jxfpxnkl | Mnrypy | $12.0 Bil |